Skip to content

A Study Investigating the Analgesic Efficacy of Oxalidine in Combination with Sufentanil Following Gynecological Laparoscopic Surgery

A Study Investigating the Analgesic Efficacy of Oxalidine in Combination with Sufentanil Following Gynecological Laparoscopic Surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500115211
Enrollment
Unknown
Registered
2025-12-23
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain

Interventions

Sufentanil group:Sufentanil 100ug
Sufentanil + Oxalidine:Sufentanil 50ug + Oxalidine 15mg

Sponsors

Jinjiang Maternal and Child Healthcare Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients experiencing moderate to severe pain following gynecologic laparoscopic surgery; 2. Aged between 18 and 65 years; 3. Without a prior history of alcohol, opioid, or drug addiction; 4. Free from depression, senile dementia, and other mental disorders; 5. Without any brain or spinal cord injury, among other conditions.

Exclusion criteria

Exclusion criteria: 1. Patients with severe comorbidities, including liver and kidney dysfunction, heart failure, myocarditis, myocardial infarction, or respiratory diseases.; 2. Individuals with a history of severe allergic reactions to opioids, such as oxycodone and sufentanil; 3. Patients with a prior history of chronic pain or prolonged use of analgesic medications; 4. Patients diagnosed with malignant tumors experiencing cancer-related pain.

Design outcomes

Primary

MeasureTime frame
Analgesic effect;

Secondary

MeasureTime frame
Effective press times of analgesia pump;Remaining drug volume of analgesia pump;

Countries

China

Contacts

Public ContactTang Xiaoqin

Jinjiang Maternal and Child Healthcare Hospital

15198055025@163.com+86 151 9805 5025

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026